Results 211 to 220 of about 2,137,840 (268)

Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study. [PDF]

Liver Int
Abosheaishaa H, Elfert K, Abusuliman M, Ismail A, Olimy A, Alzamzamy AE, Omran A, Rizzo V, Nassar M, El-Kassas M.   +9 more
europepmc   +1 more source

Chemotherapy‐Activated GSK3β‐DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma

Advanced Science, EarlyView.
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li, Shuai Ying, Yi Zhang, Jingjing Wang, Quan Wan, Lingli Gong, Daxing Xu, Zhenkun Yang, Hongnian Lu, Ying Yin, Xiangming Fang, Zhening Pu   +11 more
wiley   +1 more source

APDS treatment in Germany: decision criteria, costs and contribution of leniolisib to outcomes. [PDF]

Front Immunol
Baumann U, Deau MC, Franke K, Hanitsch LG, Sogkas G, Herrmann KH, Bosch Dos Santos U, Minartz C, Neubauer AS, Hauck F.   +9 more
europepmc   +1 more source

AARS1‐Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer

Advanced Science, EarlyView.
AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Qin Yuan, Tianbao Song, Yipeng He, Sihan Xia, Yaoqiu Huang, Wenlin He, Qin Yi, Zefeng Wang, Peihan Wang, Chenbo Huang, Linzhi Li, Zhen Yin, Fan Cheng, Weimin Yu   +13 more
wiley   +1 more source

Survival Analysis in Orthopaedics: Techniques to Evaluate Long-term Treatment Efficacy and Patient Outcomes. [PDF]

J Orthop Case Rep
Vatkar AJ, Kale S, Shyam A, Shinde S.
europepmc   +1 more source

14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

Advanced Science, EarlyView.
Integrative multi‐cohort analyses identify 14‐3‐3γ as a biomarker and regulator of cognitive vulnerability. Experimental studies show that 14‐3‐3γ loss is associated with Tau Thr205 phosphorylation, synaptic dysfunction, and cognitive impairment, while genetic overexpression or pharmacological stabilization of 14‐3‐3γ confers protective effects in ...
Shouqiang Zhu, Xue Han, Heng Zhang, Chang Ye, Tianjiao Xia, Xiaoping Gu   +5 more
wiley   +1 more source

Bridging tumor growth dynamics and survival in preclinical oncology drug development - a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework. [PDF]

Cancer Chemother Pharmacol
Niloy KK, Horn J, Bhuiyan NH, Bhosale SS, Shaaban KA, Prisinzano TE, Thorson JS, Rohr J, Leggas M.   +8 more
europepmc   +1 more source

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai, Yi Wang, Na‐Na Li, Ling Zeng, Renzhong Liu, Xue Li, Cheukfai Li, Xin‐Yu Ma, Wenkui Fu, Yingsen Tang, Jinjin Chen, Ning Liao, Man‐Li Luo   +12 more
wiley   +1 more source